Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Can One Bad Gene Patent Holder Spoil the Whole Barrel?
- In its recent move to invalidate gene patents, the ACLU focused its lawsuit on Myriad Genetics' miserly control of two genes associated with breast cancer. Which begs the question: is the problem really the thousands of issued gene patents, or is it the way a select few gene patents have...
- Blog posts 2009-06-04
Additional Resources
- Ryogen licenses human aminopeptidase P gene patent to R&D systems.
- Ryogen LLC (Suffern, NY) and R&D Systems, Inc. (Minneapolis, MN), a wholly owned subsidiary of TECHNE Corporation, announced that they have entered into a nonexclusive license agreement whereby RDSI has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene. ...
- Research articles 2006-06-01
- Gene patent fight.
- Jun 27, 2005 (New Scientist - ABIX via COMTEX) Ashkenazi Jewish women face possible discrimination in breast cancer testing. The presence of the BRCA2 gene indicates a higher risk of breast cancer. US test creator Myriad Genetics has applied for the patent on using...
- Research articles 2005-06-28
- Oncormed Files Suit Against Myriad Genetics, Inc. For Infringement of BRCA1 Gene Sequence Patent
- GAITHERSBURG, Md.--BUSINESS WIRE--November 17, 1997--Oncormed, Inc. (AMEX:ONM) today announced that it has filed suit in U.S. District Court for the District of Columbia against Myriad Genetics, Inc. The suit claims infringement of Oncormed's recently issued BRCA1 gene patent (No. 5,654,155).
- Research articles 1997-11-17
- Clinton/Blair gene patent announcement draws reaction.(Brief Article)(Statistical Data Included)
- Preliminary reports of the March 14 joint announcement by President Clinton and British Prime Minister Tony Blair concerning gene patents dropped the stock prices of Human Genome Sciences, Inc. (Rockville, MD; 301-309-8504) and Incyte Pharmaceuticals, Inc. (Palo Alto, CA) Incyte fell 30% that day, Human...
- Research articles 2000-03-01
- GENEMEDICINE Receives Broad Patent Covering the Use of Cationic Lipids for Gene Therapy
- THE WOODLANDS, Texas--BW HealthWire--October 15, 1997-- Worldwide exclusive license to Vanderbilt University patent issued in U.S. and in Europe covers widely used non-viral gene delivery technology GENEMEDICINE, INC. (NASDAQ:GMED) announced today the issuance both in the U.S. and in Europe of a major gene...
- Research articles 1997-10-15
- Introgen's mda-7 gene therapeutic receives patent.(Introgen Therapeutics, Inc.; U.S. Patent 6,355,622 issued, to Columbia University)(Brief Article)
- Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) and Columbia University (New York, NY) announced that the United States Patent and Trademark Office has issued, to Columbia University, United States Patent 6,355,622 entitled "Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell"...
- Research articles 2002-06-01
- Oncormed's BRCA1 Gene Sequence International Patent Application Published
- GAITHERSBURG, Md.--BW HealthWire--August 21, 1997--Oncormed, Inc. (AMEX:ONM) today announced that the international patent application for its BRCA1 gene sequence and related work was published on August 14, 1997. The Company recently announced that on August 5, 1997 it was issued a patent by the U.S. Patent and Trademark Office...
- Research articles 1997-08-21
- Introgen wins European patent decision on p53 gene therapeutic.
- Introgen Therapeutics, Inc. (Austin, TX) was successful in winning the decision regarding its opposition of European Patent 390 323 before the European Patent Office EPO in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's ADVEXIN molecular therapy, were...
- Research articles 2005-05-01
- Gene Shears wins European patent opposition battle against Ribozyme.(Brief Article)
- Gene Shears Pty Ltd. (Canberra, Australia) announced that the European Patent Office has maintained without amendment European Patent 0360257 after an opposition filed by Ribozyme Pharmaceuticals, Inc. (Boulder, CO; 303-449-6500). The patent has broad composition of matter and use claims for hairpin ribozymes and is...
- Research articles 2000-05-01
- University of Texas awarded patent for use of P53 gene in combination with DNA damaging agents utilizing any type of delivery system.(Brief Article)
- The University of Texas (Austin, TX; 512-499-4462) and Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) announced that the United States Patent and Trademark Office has issued to The University of Texas United States Patent 6,069,134, titled, "Methods and Compositions Comprising DNA Damaging Agents and p53." The...
- Research articles 2000-06-01
- IBEX Technologies Inc. - U.S. and European Patents for Heparinase Gene Awarded
- MONTREAL--BUSINESS WIRE--Sept. 10, 1997--IBEX (ME, TSE IBT. ) A Notification of Allowance for a US Patent Application claiming the heparinase I gene from Flavobacterium heparinum has been issued by the US Patent and Trademark Office and by the European Patent Office. This patent, assigned to the...
- Research articles 1997-09-10
- Ryogen Gets Patent on Soluble Aminopeptidase P Gene
- SUFFERN, N.Y. -- Ryogen LLC announced today that it has been awarded a patent by the U.S. Patent and Trademark Office for the soluble aminopeptidase P gene. US Patent No. 7,273,718, entitled "Isolated Genomic Polynucleotide Fragments from Chromosome 10q25.3 that Encode Human Soluble Aminopeptidase P", was issued on September 25,...
- Research articles 2007-10-29
- Introgen's viral vector technology awarded patent.(Introgen Therapeutics Inc. licenses patent from the University of Texas on hindering viruses)(Brief Article)
- The University of Texas (Austin, TX; 512-499-4462) and Introgen Therapeutics, Inc. (Austin, TX; 512-708-9310) announced that the United States Patent and Trademark Office has issued to The University of Texas United States Patent 6,110,744, titled, "Diminishing Viral Gene Expression By Promoter Replacement." The patent...
- Research articles 2000-11-01
- Targeted Genetics expands patent portfolio for program.(Targeted Genetics Corp.U.S. Patent 6,395,712 issued to the University of Texas M. D. Anderson Cancer Center)(Brief Article)
- Targeted Genetics Corporation (Seattle, WA; 206-521-7823) announced the issuance of an additional patent related to its E1A gene therapy program for the treatment of cancer. The patent , United States Patent 6,395,712, "Sensitization of HER-2/Neu Overexpressing Cancer Cells to Chemotherapy," issued to...
- Research articles 2002-06-01
- CyGene Laboratories Receives U.S. Patent Office Notice of Allowance for Next Generation Gene Therapy Technology
- Ewire -- CyGene Laboratories, Inc. (OTC BB: CYGEE) announced today that the United States Patent and Trademark Office has approved and will issue a patent for the company's next generation gene-capture technology. Although developed for the highly efficient capture of genetic sequences for diagnostic purposes, the greatest commercial potential for...
- Research articles 2004-07-22
- Clinical Data Secures EU Patent for MDR1 - A Key Multi-Drug Resistance Gene
- Gene Linked to Response to Many Classes of Medications NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that the European Patent Office has granted Patent No. 1232260 to...
- Research articles 2008-06-26
- Introgen Wins European Patent Decision on p53 Gene Therapeutic; Ruling Clears Path to Commercialization of ADVEXIN(R) in Europe.
- AUSTIN, Texas, June 2 /PRNewswire/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office EPO in which all claims directed to ...
- Research articles 2005-06-03
- Diversa announces issuance of patent reinforcing rights for discovery of enzymes.(Brief Article)
- Diversa Corporation (San Diego, CA; 858-860-0266) announced the issuance of United States Patent 6,280,926, covering the discovery of enzymes from gene libraries derived from mixed populations of eukaryotic organisms, such as fungi, plants, and insects and prokaryotic organisms such as bacteria and archaea. This...
- Research articles 2001-09-01
- Gene Logic Drug Repositioning Program Discovery Results in Filing of New Therapeutic Use Patent by Pfizer
- GAITHERSBURG, Md. -- Gene Logic Inc. (NASDAQ: GLGC) announced today recognition of a collaboration milestone, triggered by the filing of a patent application for a new use of an existing Pfizer drug candidate to treat solid tumors. The new use for the unapproved drug candidate was discovered by Gene Logic's...
- Research articles 2007-11-20
- << Previous
- page 1 of 1
- Next >>
Presented by American Express